Corcept Therapeutics has appointed Gary Robb as chief financial officer (CFO). Robb will oversee Corcept’s financial operations, including preparations for potential commercialisation of its first product, business development activities, investor relations, and along with other members of the management team, corporate strategy.
Before joining Corcept, Robb served as senior vice president (SVP) of operations, administration and finance at Fitness Anywhere (FAI), a private fitness equipment and training company with operations in the US, Europe and Asia. Robb’s responsibilities at FAI included finance, legal affairs, human resources, management information systems, supply chain, distribution and logistics and management of the intellectual property portfolio.
Robb has more than 25 years of experience in executive management, operations and finance. From 2000 to 2002 he was SVP of Citadon, where he was founder of a division responsible for developing workflow and analytic software for real estate lenders with responsibilities including development of the division’s strategy, marketing, budgeting, sales and mergers and acquisitions. He has also held positions in business development for Normura Asset Capital and in sales and marketing for Legal Research Network.
From 1992 to 1996 Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Robb earned a BA in english and political philosophy from Yale and a J.D. from Harvard Law School, where he was a member of the Harvard Law Review.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.